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Highlights 
 
 Abuse of prescription opioids is widespread within prisons. 
 There is significant variation internationally in the type of opioid abused. 
 Further research is needed regarding how to effectively respond to such 
abuse. 
 Assertiveness and safer prescribing training for prescribing staff is needed.  
 More research is required on the development of less abuseable 
preparations. 
 
 
Abstract 
Background 
To systematically review the quantitative and qualitative evidence base pertaining to 
the prevalence, practice of, and treatment response to the diversion of prescribed 
opiates in the prison setting.  
Methods 
Medline, Embase, CINAHL, PsycINFO, Google Scholar, ASSIA and Science Direct 
databases were searched for papers from 1995 to the present relevant to the abuse 
of prescribed opiate medication. Identified journals and their reference lists were 
hand searched for other relevant articles. Of the abstracts identified as relevant, full 
text papers were retrieved and critiqued against the inclusion criteria for the review.  
Results  
Three hundred and fifty-five abstracts were identified, leading to 42 full-text articles 
being retrieved. Of those, 10 papers were included in the review. Significant 
differences in abuse behaviours between different countries were reported. 
However, a key theme emerged from the data regarding a culture of nasal 
administration of prescribed sublingual buprenorphine within some prisons due to 
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both reduced prevalence of injection within prison and reduced supplies of illicit 
drugs within prison. The buprenorphine/naloxone preparation appears to be less 
amenable to abuse. The review highlighted a paucity of empirical research pertaining 
to both prevalence of the phenomenon and treatment responses. 
Clinical and research implications 
Healthcare providers within prisons need to prescribe opioids in the least abuseable 
preparation since the risk of abuse is significant, despite widespread processes of 
supervised dispensing. Prescription medication abuse is not limited to opioids and 
the predominant drug of abuse in an individual prison can rapidly change according 
to availability. 
Keywords  
Abuse of prescribed medication, Opioid, Buprenorphine, Buprenorphine/Naloxone, 
Oxycodone, OxyContin, Methadone, diversion, prison, prisoner, abuse, misuse. 
 
 
 
1.0. Introduction  
Recent estimates suggest there are between 15 and 39 million problem opioid users 
worldwide (Degenhardt and Hall, 2012). This is part of a much larger estimated 
number of between 162 million and 324 million people who, in 2012, had used any 
illicit drug (World Drug Report, 2014). Such users are disproportionately represented 
in the criminal justice system (Dolan et al., 2007; Fazel, 2006). For example, in 
America, over 200,000 opioid dependent prisoners pass through the correctional 
facilities annually, and it is estimated that more than 50% of prisoners in the USA 
have a history of substance misuse (Mumola and Karberg, 2006; Nunn, 2012). It is 
 4 
also widely accepted that prison is a high-risk environment, which makes some 
prisoners vulnerable to initiation of drug use, including heroin (Boys et al., 2002). 
However, upon entering prisons, many opiate users cease injecting and, due to 
security processes that disrupt trafficking into prisons, resort to obtaining supplies 
through other means, including opiates prescribed in the prison setting. Such a 
practice makes these prisoners vulnerable to harassment (Wright et al., 2015).  
 
Whilst historically, prisoners have been denied opiate substitution treatment 
(National Quality Forum, 2007), recently in the UK there has been a significant 
increase in the prescribing of opiate substitution treatment in prison settings (Wright 
et al., 2014a).  Typically, opioid substitution treatments are either methadone or 
buprenorphine (Nunn et al., 2009).  In addition to the trend of increased prescribing 
of opioid substitution therapy in prison settings, many prisoners present with co-
morbid physical health problems resulting in pressure for prison-based clinicians to 
prescribe opioids and there has been increasing concern amongst both clinicians 
and policy leads regarding the abuse of such prescribed opioids in prison settings 
(Public Health England, 2013). 
 
The US National Institute of Drug Abuse (NIDA) defines Prescription Drug Abuse as 
“the use of a medication without a prescription, in a way other than as prescribed, or 
for the experience or feelings elicited” (2014).  This definition concurs with the WHO 
definition of Psychoactive Substance Misuse as the “use of a substance for a 
purpose not consistent with legal or medical guidelines, as in the non-medical use of 
prescription medications”. The term is preferred by some in reference to abuse in the 
belief that it is less judgemental (World Health Organisation, 2015). Therefore, our 
 5 
review considered “abuse” of prescription opioids as defined by administering legally 
prescribed medication through unlicensed routes such as injecting, smoking or 
intranasal administration (commonly referred to in the literature as snorting or 
sniffing); or diversion which is defined as the transfer of medication from a lawful to 
an unlawful channel of distribution (NIDA, 2014). Diversion of prescribed opioids, 
particularly methadone, is a global public health problem due to increased risk of 
overdose fatalities (Madden and Shapiro, 2011). It has also led to an increase in the 
incidence of opioid dependence (particularly in regions where, or periods when, 
heroin availability is scarce) and therefore has compromised the public acceptance 
of long-term opioid prescription (Bell et al., 2009).  
 
Diversion of prescription opioid methadone, or buprenorphine, maintenance 
medication is common. In community populations, self-report estimates range from 
16 to 60% (Davis and Johnson, 2008; Gwin Mitchell et al., 2009; Winstock et al., 
2008). Almost 20% of individuals inject opioid maintenance medication that is 
prescribed for either oral, or sublingual, consumption (Winstock et al., 2008).  
A variety of motivations have been cited for buying illicit prescription opioids: a desire 
for a euphoric experience, to ameliorate symptoms of opiate withdrawal, or to control 
symptoms of pain. In highlighting different motivations, the authors reported that the 
group who used prescribed medication for euphoria were also more likely to divert 
such medication. They suggested concentrating criminal justice efforts on these 
groups rather than on users who tended to use illicit prescribed medication for 
amelioration of either withdrawal or pain symptoms (Davis and Johnson, 2008).  
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However, prescription medication abuse is not limited to community settings and has 
been highlighted as a major concern amongst prison populations (Hendrich et al., 
2011; Singleton et al., 2003). A descriptive survey commissioned by the UK Ministry 
of Justice (MOJ) found that of 139 prisons in England and Wales surveyed between 
February and April 2007, 87 of these prisons detected buprenorphine in random 
and/or targeted Mandatory Drug Tests (Ministry of Justice, 2007). Buprenorphine 
misuse was far more widespread across the country and across prison categories 
than anticipated. It was identified to be the most misused drug in eleven prisons, and 
the third most misused drug overall (Ministry of Justice, 2007).  
 
Commonly prescribed opioids in UK prison settings include methadone and 
buprenorphine. Methadone is currently prescribed in UK prisons in the liquid 
preparation as it is seen as less amenable to diversion than tablet preparations. 
Buprenorphine is currently prescribed in sublingual preparation either as the mono-
buprenorphine product or as the combination buprenorphine/naloxone product 
(Wright et al., 2012). Internationally, there have been reports of abuse of both 
prescriptions in the prison and community setting. Gordon et al. (2011) report in their 
paper that buprenorphine prisoner patients are more likely to be terminated from 
their treatment in prison for potential diversion of the medication. The criminal justice 
system in the USA is, therefore, reluctant to prescribe opioid treatment (Kinlock et 
al., 2009; Nunn et al., 2009), with a strong preference of having drug-free prisons 
(Schwartz et al., 2011).  
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Therefore, in light of the growing problem relating to prescription opioid abuse in 
prison settings, it felt timely to undertake a review of prevalence, risk factors, and 
interventions for prescription medication abuse.  
 
2.0. Methods  
MEDLINE, CINAHL, The Cochrane Library, PsychINFO, EMBASE, ASSIA and 
Science Direct databases were searched in ATHENS from the period of January 
1995 through October 2015 using internationally accepted MeSH headings outlined 
in Table 1. The date range reflects the fact that prescription opioid abuse in prisons 
is a relatively recent problem. Therefore, little empirical evidence had been collected 
before 1995. Full text articles were also hand searched by examining the reference 
list for other studies of relevance not identified through the electronic searches.  
Google Scholar was accessed to search for empirical grey literature.  
  
2.1. Inclusion and Exclusion Criteria    
Quantitative or qualitative empirical research studies either exploring or evaluating 
the risk of abuse of prescribed opioids in prison settings met the inclusion criteria.       
The search was limited to human studies published in the English language.  
Studies that considered the following were excluded: 
 Abuse of non-opioid drugs  
 Opinion pieces or discussion papers  
 Pharmacokinetic or pharmacodynamic studies 
 Papers exploring diversion in the community (i.e., non-prison) settings    
 
2.2. Study Selection 
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Abstracts of identified papers were independently assessed against the inclusion 
and exclusion criteria by ZM and NW. Discrepancies were resolved by consensus 
meetings between ZM, NW and PH.  Following this process, full papers were 
retrieved for review by ZM.  
 
2.3. Quality Assessment  
The quality of quantitative papers was assessed using a checklist (see Table 2) 
devised from the UK National Institute for Health and Care Excellence (NICE) 
guidelines manual and the Cochrane Handbook for Systematic Reviews (NICE, 
2012; Higgins and Green, 2011).  
 
It is acknowledged that whilst there is no consensus regarding the application of 
quality criteria to qualitative research papers, many accept the need for clear and 
transparent approaches for judging the quality of such research (York University 
Centre for Reviews and Dissemination, 2009). To this end, quality of qualitative 
research was assessed using the CASP framework (see Table 3)(Casp,2013). Such 
use of checklists at the stage of synthesising the data facilitated assigning greater 
prominence to findings from papers that had more methodological rigour. 
 
3.0. Results  
Three hundred and fifty-five abstracts were identified from the electronic databases. 
Two hundred and eighty-one were excluded because they did not meet the inclusion 
criteria and 32 duplicate abstracts were excluded, leaving 42 abstracts for which full 
texts were obtained for review (see figure 1). A total of ten papers met the criteria for 
inclusion (see table 4). 
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The limited research findings highlighted differing practices of opioid abuse in prison 
settings. Such practices are outlined below. We did not retrieve any prevalence 
studies pertaining to prescription opioid abuse. Also, we did not retrieve any studies 
pertaining to treatment interventions aimed at reducing the risk of prescription opioid 
abuse. Therefore, the findings reported below relate to themes emerging from the 
data regarding differing practices of prescription opioid abuse and how factors 
external to the individual (e.g., the prison environment itself) impact upon such 
practices. The themes were derived from applying the checklists highlighted in 
Tables 2 and 3 to the included paper 
 
3.1. Heterogeneity of Prescription Opioid Abuse Practice 
The review highlighted prescription opioid abuse in prisons as an international 
phenomenon, as evidenced by data reported in the USA, Canada, UK and Australia. 
However, significant differences in abuse behaviours between different countries 
were reported. 
 
The Horyniak et al. (2011) Australian study highlighted the practice of unlicensed 
inhaling buprenorphine, which was more common amongst individuals who had a 
history of imprisonment. Inhaling buprenorphine was typically practiced as “chasing” 
off foil. However, none of the other studies included in this review highlighted such a 
practice. Also, the authors highlighted regional differences between different 
jurisdictions in Australia. Therefore, such a practice is possibly confined to certain 
regions within the Australian subcontinent.  
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The theme of regional variation of abuse of prescription opioids is supported by the 
findings of the Johnson et al. (2012) Canadian research that surveyed over 1200 
male prisoners who were being prescribed methadone for maintenance. They found 
significant regional differences in the prevalence of both morphine/hydromorphone 
and oxycontin unlicensed use. The study by Wunsch et al., which was conducted in 
the USA in the context of widespread media publicity regarding unlicensed oxycontin 
use, highlighted both age and gender variations in the unlicensed use of prescribed 
oxycontin. Females and those under the age of 30 were more likely to abuse 
oxycontin. Oxycontin abuse was also associated with wider poly-drug misuse of 
prescribed medication. 
 
Oxycontin abuse was not reported in either UK or Australian cohorts. Rather, 
buprenorphine abuse appeared to be a phenomenon reported amongst UK and 
Australian cohorts and the unlicensed nasal route of administration appeared to be 
almost exclusive to the prison setting. It would appear that the reduced prevalence of 
injection and the reduced supply of drugs contribute to a culture of unlicensed nasal 
administration of buprenorphine within some prisons (George and Moreira, 2008; 
Horyniak et al., 2011; Tompkins et al., 2009; Wright et al., 2015).  
 
3.2. Impact of the Prison Setting upon Prescription Opioid Abuse 
In their 1998 UK survey, Swann and James found that 10% of the sample stopped 
using all opioids in prison as they had “reached their time” (1998). For those who 
continued, most reduced due to the cost and limited availability of drugs and there 
was a tendency to switch drugs according to whatever was available. Only a small 
minority used prescription opioids inside the prison, namely diverted methadone. 
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This finding of a small proportion of the prison population using diverted methadone 
is supported by the data from Marriott et al., in which one participant reported such 
use (2008). This was a study conducted in 2002-03, which was before the 
implementation of prescribed methadone treatment into the study site.  
 
However, in later UK based qualitative research conducted by Tompkins et al. 
(2009), during which, male ex-prisoners were interviewed between 2006 and 2008, a 
significant theme of unlicensed intranasal use of buprenorphine emerged. Crucially, 
this form of prescription medication abuse was not limited to prisons in which the 
medication was prescribed; i.e., there is diversion into prison of buprenorphine 
prescribed in community settings. That said, the primary source was diversion of 
prison prescribed opioids and participants described a variety of techniques used to 
divert buprenorphine administered via the sublingual route. Such techniques 
involved seeking to evade the monitoring process of supervised consumption (also 
referred to as directly observed therapy) by concealing the medication in an area of 
the mouth other than the sublingual area, substituting sublingual buprenorphine with 
a different tablet (typically paracetamol), or removing the tablet when the gaze of 
observing discipline or nursing staff was distracted. Prisoners reported variability 
between professionals in the stringency of observing administered buprenorphine 
medication. The widespread unlicensed use of buprenorphine was primarily linked to 
availability, although cost of diverted prescribed buprenorphine varied between 
establishments; i.e., as would be expected, the cost was higher in prisons where the 
medication was not prescribed. However, a relative loss of tolerance to opioids on 
account of reduced prison supply meant that users experienced a heightened 
euphoric effect due to occasional use. They also reported a long duration of euphoric 
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action through nasal administration of buprenorphine (i.e., up to 24 hours) and 
therefore, it was expedient to use such medication in prisons. They reported that the 
nasal route of administration intensified the euphoric effect. Additional motivators for 
such use were described as an escape from the monotony of prison life. For some, 
they reported that using buprenorphine was less likely to lead to formal sanctions if 
caught by prison authorities, as it is an opioid that has licensed medicinal use. 
However, for others, this was a disincentive, since the risk of getting caught 
heightened the pleasure of illicit opioid use. Despite small sample sizes, the data 
possibly highlights a trend away from small-scale use of diverted methadone abuse 
in UK prisons to widespread unlicensed use of diverted buprenorphine.  
 
Our review highlighted a paucity of international data exploring this trend. Indeed, the 
only relevant international data that we identified was that of descriptive data 
pertaining to secondary outcomes in the USA, a randomised controlled trial 
conducted by Magura et al. (2009). The authors reported that six buprenorphine 
patients and one methadone patient had their medication stopped due to attempted 
diversion (comparative statistics were not provided). 
 
Woodall highlighted staff constraints as a significant factor in controlling illicit opioid 
use within prisons; i.e., staff shortages due to either budgetary constraints or long-
term staff sickness (2011). Woodall’s findings confirm Tompkins et al.’s findings of 
boredom as a motivator to use such medication (2011; 2009). Woodall also 
highlighted one case report suggesting regional variation, in that establishments in 
the South of England did not have a problem with buprenorphine misuse (2011). 
However, the theme of buprenorphine misuse in prison was confirmed in the 
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research undertaken by George and Moreira, who, in interviewing patients recently 
released from prison attending a community drug service, found that intranasal 
administration of buprenorphine was a practice almost exclusive to the prison setting 
(2008). Participants stated the following motivators for such a behaviour: it is safer 
than injecting, the ease of procurement in prisons, and the rapid and intense onset of 
action. Published in 2008 (the date of recruitment was not stated), participants at that 
time were unaware prior to imprisonment that buprenorphine could be administered 
intranasally. 
 
3.3. Abuse Potential of Buprenorphine/Naloxone Compared to Mono-Buprenorphine 
A theme emerged that mono-buprenorphine was more likely to be abused than the 
buprenorphine-naloxone preparation. This theme is evidenced by price differentials 
between the two preparations highlighted in the Wright et al. UK based study 
(2014b). Further evidence is found in the Horyniak et al. study, which explored the 
finding that across three Australian jurisdictions, compared to inhaling 
buprenorphine-naloxone, there were higher rates of inhaling mono-buprenorphine 
(2011). Similarly, compared to snorting buprenorphine-naloxone, there were higher 
rates of snorting mono-buprenorphine. Whilst participants were recruited from a 
community sample, the findings are relevant to this review since the sample that 
report having ever inhaled buprenorphine, were statistically significantly more likely 
to have had a prior history of imprisonment.  
 
4.0. Discussion 
4.1. Summary of Key Findings 
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In summary, our review found that, internationally, there were differing practices of 
prescription opioid abuse. Intranasal administration of buprenorphine sublingual 
tablets was reported in UK studies and, for some participants, they were unaware of 
this route of abuse prior to entering prison. The source of prescribed opiates in 
prison drug markets is not limited to prison based prescribers, although diversion of 
prison prescribed opiates is common. Financial and organisational constraints upon 
discipline staff quotas can severely restrict security responses to reducing both the 
trafficking of prescribed drugs into the prison and diversion of prison prescribed 
medication. There appears to be a paucity of robust treatment responses to the risk 
of prescription opioid abuse in prison settings, although there is survey evidence that 
suggests that buprenorphine/naloxone preparation is less amenable to abuse than 
the mono-buprenorphine preparation. Crucially, prisoners have developed 
sophisticated behavioural techniques to evade the monitoring process of supervised 
consumption of medication.  
 
The strength of our research is that insofar as we are aware this is the first 
systematic review of the prevalence, practice and treatment responses to prescribed 
opiate abuse in prison settings. The lack of quality empirical research is 
disappointing given the high prevalence of opiate abuse, co-morbid health conditions 
and associated risk taking behaviours by prisoners (Milloy et al., 2008). In particular, 
we did not retrieve any research pertaining to treatment responses to minimise the 
risk of prescription medication abuse. In the absence of such evidence, current 
practices include crushing tablets, opening capsules, and mixing the content with 
jam in an attempt to reduce diversion, with little evidence to support the value of 
such practices (Pilkinton and Pilkinton, 2014). Therefore, more research is needed in 
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this area to evaluate interventions to support safer use of prescribed medications in 
prisons. The findings of the review did not retrieve any research pertaining to which 
prisoner subgroups are particularly vulnerable to either harassment or bullying 
attempts to divert medication. It is possible that some prisoners, due to age, co-
morbid mental health problems, or learning disabilities, will be particularly vulnerable 
and this illustrates an additional area that merits further research activity. 
 
Pending such developments, several strategies have shown promise, including 
prescribing forms of medication, which are less amenable to abuse (for example; 
liquid rather than tablet preparations).  Also, the practice of crushing buprenorphine 
tablets prior to administration has been suggested as an effective practice to reduce 
the risk of buprenorphine diversion whilst not altering the bioavailability of the 
medication (Simojoki et al., 2010; Strain et al., 2004). However, crushing of 
prescribed tablets is unlikely to be a long-term solution to the problem of 
buprenorphine diversion in prison settings. Rather, development and implementation 
of new buprenorphine preparations have the potential to minimize the risks of illicit 
diversion. Safety, efficacy and pharmacokinetic data from an open label trial of a 
buprenorphine implant showed promise, albeit with the significant limitation of the 
sample size being just twelve participants (White et al., 2009). Also, a phase II trial of 
a buprenorphine depot monthly injection is currently ongoing with Reckitt Benckiser 
Pharmaceuticals Inc. (ClinicalTrials.gov, 2014). If trials of such products demonstrate 
efficacy and effectiveness comparable with buprenorphine sublingual tablets, then it 
is probable that they will become the first line buprenorphine preparation prescribed 
in prison settings, since implant/depot preparations are, by their very nature, less 
easy to divert than tablet preparations. 
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In addition to new product developments, more research is required regarding the 
potential of wider developments in service delivery and organisation to reduce the 
risk of prescription opioid abuse. Such developments could entail training for staff in 
protocols for medicines management and assertiveness training for prescribing, 
dispensing and administering clinicians.    
 
4.2. Changing Trends of Prescription Medication Abuse in Prisons 
Our review highlighted changing trends in prescription medication abuse in prisons, 
with early studies highlighting a practice of methadone diversion (albeit very low 
prevalence of such practice), whereas latter studies concurred regarding the high 
prevalence of buprenorphine diversion.  
 
However, there have been recent anecdotal reports regarding possible trends 
towards non-opioid analgesic abuse. In particular, tramadol, pregabalin, and 
gabapentin have been highlighted in UK guidance to prison doctors as medications 
with significant abuse potential in prison settings (Centre for Social Justice, 2015; 
Royal College of General Practitioners and Royal Pharmaceutical Society, 2011). 
The typical presentation is that of patients with a history of drug dependence 
presenting with symptoms of musculoskeletal pain. Assessing whether the 
presentation of pain is credible or in fact a hidden agenda to obtain prescription 
drugs for subsequent diversion can be difficult. It is possible that future organisation 
and delivery of healthcare in prisons will benefit from integrated working between 
addiction services and pain management services.  
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There are also anecdotal reports of sedative antidepressant and psychotropic abuse 
in prisons (Pilkinton and Pilkinton, 2014). The popularity of such non-opioid 
prescribed medications appears to be either in the euphoric feeling or the sedative 
action, which helps with troubling symptoms of insomnia (Wright et al., 2012). 
Prescribing practitioners believe that such attempts to divert prescribed medication 
threaten client stability of an already vulnerable population and impede effective care 
planning and treatment (Baldwin and Duffy, 2013). 
 
5.0. Conclusion   
In conclusion, prisons are settings susceptible where individuals are vulnerable to 
the effects of diversion of prescription opioid abuse. Pending new product 
developments that have lower abuse potential than existing medications, we would 
suggest that opioid drugs are prescribed in the least abuseable form, particularly 
since current evidence would suggest that prisoners have developed sophisticated 
behaviours to divert prescribed opioids, despite apparently stringent supervised 
dispensing regimes. Prescribing of opioids in prison will require a balance between 
not under-dosing (as such a practice will potentially trigger patients to seek illicit 
opioids to reach a steady state), whilst also avoiding excessive prescribing, since 
such prescribing practices would increase the volume of medication available for 
diversion. The type of medication abused in prisons varies widely between countries. 
Also, such abuse is not limited to opioids, and the predominant drug of abuse in an 
individual prison can rapidly change according to availability. Some prisoners, on 
account of age or co-morbid mental health problems, will be particularly vulnerable to 
harassment or bullying attempts for them to divert medication.  
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Figure 1.  
 
 
Figure 1. The PRISMA ‘Literature Search’ map. 
 
Following review, ten studies met the inclusion criteria and the demographic details, 
methodologies, outcomes and results are summarised in Table 4.  
 
Table 1: Search words related to the study 
A Literature Review Map 
Identified (N=355) studies from search 
terms 
 
Records obtained for full review:  
Studies related to buprenorphine, 
buprenorphine/naloxone, oxycodone, 
oxycontin hydromorphone,  
methadone, diversion, abuse of 
prescription medication, prison, jail, 
prisoners, prison and abuse, misuse 
(N =43) 
 
Abstracts sifted for 
relevance to topic with 281 
excluded  
Records screened for 
duplicates, excluded 32 
 
Report finding based on the following studies: (N=10)  
 
 
 
 
 
 (N=42) 
 
 
 
(N=10) 
Assessed for eligibility to criteria 
Full text papers not 
specific to prison (N= 33) 
 
(N=42) 
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Word group 1 Word group 2 Word group 3 
opioid abuse  prison  
opioids  diversion  prisoners  
buprenorphine  misuse  correctional services  
buprenorphine/naloxone   sale  penitentiary  
morphine   jail 
methadone    
dihydrocodeine    
codeine    
oxycodone    
diamorphine    
opiate alkaloids/or opiate 
substitution treatment 
  
substance abuse detection/ 
or opioid related disorders 
  
behaviour, addictive/ or 
drug prescriptions/ or drug 
and narcotic control 
  
Notes: Boolean operators 
words within groups combined 
with OR. Groups combined 
with AND. 
Notes: words within groups 
combined with OR. Groups 
combined with AND. 
Notes: words within 
groups combined with 
OR. Groups combined 
with AND. 
 
Table 2: Criteria used to Assess the Quality of Quantitative Studies  
 
Randomised Controlled Studies 
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 Process of randomisation clearly described and whether open, single blind, or 
double blind 
 Process of concealment clearly described 
 Steps taken to avoid contamination 
 Steps taken to ensure independence of data analysis from the clinical 
intervention 
 Clear explanation of how missing data was accounted for e.g., use of intention 
to treat analysis or multiple imputation methods 
Quasi-experimental studies 
 Baseline data reported 
 Potential for selection bias described and accounted for in the analysis 
 Potential for confounders described and accounted for in the analysis 
 Steps taken to ensure independence of data analysis from the clinical 
intervention 
Observational cohort studies 
 Use of a control group 
 Potential confounders described with an attempt made to quantify the effect 
either by study design or by statistical analysis 
 Potential for loss to follow up bias described and accounted for in the analysis 
 
Table 3: (Tools and Checklist:  CASP, 2013) 
1. Is a qualitative methodology appropriate? 
2. Is there a clear statement of the aims of the research? 
3. Was the research design appropriate to address the aims of 
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the research? 
4. Was the recruitment strategy appropriate to the aims of the 
research? 
5. Was data collected in a way that addressed the research 
issue? 
6. Has the relationship between researcher and participants 
been adequately considered? 
7. Have ethical issues been taken into consideration? 
8. Was the data analysis sufficiently rigorous? 
9. Was there a clear statement of findings? 
10. How valuable is the research? 
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Table 4: A Table outlining Study Characteristics of Papers included 
 
Authors Demographics Methodology Outcomes Results 
Horyniak et al. 
(2011) 
Australia: 372 opioid 
substitution treatment clients 
recruited through pharmacies 
and clinics across three 
jurisdictions in Australia. 238 
male, 134 female. 175 over 35 
years of age, 195 under 35 
years of age or younger. 
Ethnic background not stated. 
Data collected March-June 
2008. 
Cross-sectional 
survey with 
subgroup analysis 
for history of 
imprisonment 
 Prevalence of buprenorphine and 
buprenorphine-naloxone inhalation 
(typically “chased” on foil) 
 Multivariate analysis to identify key 
demographic and treatment 
characteristics correlated to 
buprenorphine inhalation  
 
 Sixty-five participants self-reported to 
ever having inhaled buprenorphine. 
Of these, 77% reported smoking 
buprenorphine and 32% reported to 
smoking buprenorphine-naloxone. 
Snorting was less common with 6% 
reporting to ever have snorted 
buprenorphine and only 2% reporting 
to have ever snorted buprenorphine-
naloxone 
 Key correlates of buprenorphine 
inhalation were 35 years of age or 
younger (OR 2.92, CI 1.77-5.44); 
history of imprisonment (OR 1.85, CI 
1.02-3.35) and history of injecting 
buprenorphine (OR 2.4, CI 1.27-
4.53).  
 Regional variation of buprenorphine 
inhaling practice (clients from 
Southern Australia jurisdiction 
significantly more likely to have ever 
inhaled buprenorphine than those 
from New South Wales and Victoria 
jurisdictions) 
George and 
Moreira (2008) 
UK: 6 heroin dependent 
patients from a NHS tier 3 
community drug treatment 
clinic in Birmingham; identified 
from 30 patients recently 
released from prison and 
responding in the affirmative to 
if they had ever snorted 
subutex. 5 male, 1 female. 
Mean age of 32.7. All White 
Case series: “semi-
structured 
questionnaire with 
quantitative and 
qualitative 
components” 
Establish reasons for and participant 
experiences of snorting buprenorphine 
 Practice of snorting buprenorphine 
seemed almost exclusive to the 
prison setting 
 Participants snorted buprenorphine 
on average 4.8 times whilst in prison 
(mean duration of prison sentence 
when snorted was 0.9 years) 
 The reasons provided for snorting 
buprenorphine were; ease of 
obtaining the drug, safer than 
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British. Dates of data collection 
not reported.  
injecting intravenously, peer influence 
and only needing a small amount of 
the drug for a euphoric effect 
 The experiences of snorting 
buprenorhine included positive 
effects of a rapid onset euphoric 
feeling; negative effects of itchiness, 
unpleasant taste and burning 
sensation in the nose  
Johnson et al. 
(2012) 
Canada: 1272 male federal 
offenders admitted to the 
Correctional Service Canada’s 
methadone maintenance 
treatment programme that had 
completed the Substance 
Abuse Assessment 
Questionnaire between 2003-
08. 80.8% of sample 
Caucasian. Mean age of 33.8 
at admission to prison.  
Cross-sectional 
survey 
 Prevalence levels of illicit 
substance misuse 
 Univariate analysis of temporal 
and regional patterns of illicit 
substance misuse 
 Risk factors associated with illicit 
substance misuse 
 70% of participants reported to using 
opioids during their current period of 
imprisonment 
 Significant regional differences 
existed for prescription opioid abuse, 
specifically for 
morphine/hydromorphone (range 
83.2% in Atlantic region vs 17.9% 
Pacific region, X2   305.7 p< 0.001, 
Cramer’s V 0.49) and oxycodone use 
(range 25.4% in Atlantic region vs 
4.2% Pacific region, X2   100.0 p< 
0.001, Cramer’s V 0.28) 
Tompkins et al. 
(2009) 
UK: 30 males who were former 
prisoners and had history of 
injecting drugs. Mean age of 
34. 24 White British, 2 Asian 
British, 2 White Other, 1 Black 
British, 1 Black Caribbean. 
Data collected August 2006-
January 2008.  
 
 
Qualitative 
interview 
 Explore drug using practices in 
prison 
 Explore how buprenorphine is 
obtained in prison and the reasons 
for its use 
 The snorting of buprenorphine in 
prison has become more widespread 
– participants indicated it was the 
opioid of choice 
 Buprenorphine was reported to be 
obtained through prisoners in receipt 
of the drug diverting it and also 
through those entering prison 
‘plugging’ community prescriptions of 
the drug and bringing it into prison 
with them 
 Reasons provided for snorting 
buprenorphine in prison included; 
increased availability, the long-lasting 
euphoric effect the drug has and that 
it is cheaper than heroin 
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Magura et al. 
(2009) 
USA: 116 heroin dependent 
males within Rikers Island 
Correctional Facility. 61 
Hispanic, 25 Black (full ethnic 
demographic not reported). 
Mean age of 39. Data 
collected August 2006-07.   
Randomised 
controlled trial (post 
hoc data collection 
pertaining to 
attempted diversion 
of prescription 
interventions) 
Compare the effectiveness of 
buprenorphine v methadone 
maintenance in custody 
 Primary outcomes; treatment 
completion in custody and 
reporting to designated treatment 
modality post-release 
 Secondary outcomes; intention to 
continue with treatment post-
release, presentation at 
medication clinic post-release, re-
imprisonment, re-arrest (and if so 
severity) and post-release use of 
illicit opioids 
 Six buprenorphine patients and one 
methadone patient had their 
medication stopped due to attempted 
diversion (comparative statistics not 
provided) 
 
Wunsch et al. 
(2007) 
USA: 233 prisoners and 
probationers (proportions not 
described) within District 28, 
Radford, Virginia. 175 male 
and 58 female. Mean age 32 
for males and 30 for females. 
Ethnic background not stated.  
Retrospective 
review of routinely 
collected cross-
sectional data from 
the addiction 
Severity Index 
2000-2004.  
Establish the abuse of prescription 
medications amongst participants with 
a criminal record in South-western 
Virginia, particularly the abuse of 
OxyContin due to the publicity in the 
USA regarding oxycontin abuse 
 Females were more likely than males 
to abuse prescription opioids (62.1% 
v 33.7%, p<0.001)  
 Percocet was the most abused opioid 
(29.9% males and 46.6% females) 
 Those under 30 years or age were 
more likely to use OxyContin than 
those 30 years of age or over (38.4% 
v 25%, p<0.005) 
 OxyContin abusers were more likely 
than non-OxyContin abusers to 
abuse other prescription opioids 
(87.7% v 13.8%, p<0.001), 
methadone (24.7% v 2.6% p<0.001), 
benzodiazepines (37% v 10.7%, 
p<0.001) and cocaine (52.1% v 27%, 
p<0.001) 
 Individuals reporting non-medical use 
of oxycontin were more likely than 
those who had never used oxycontin 
non-medically to have committed 
shoplifting (36.8% vs 19.1% p<0.01) 
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drug crime (60.0% vs 43.7 p<0.05) or 
forgery (40.0% vs 20.0% p<0.001) 
but less likely to have committed 
offences of disorderly conduct (41.5% 
vs 55.6% p<0.05) or driving whilst 
intoxicated (37.2% vs 51.1% p<0.05) 
. Differences regarding history of 
imprisonment were inconclusive 
Swann and 
James (1998) 
UK: 85 prisoners from one 
Category B prison in England. 
Gender, age and ethnic 
background of participants not 
stated. Dates of data collection 
not stated.  
Cross-sectional 
survey of a random 
sample of 145 
prisoners (61% 
response rate) 
 Drug use prior to and during 
imprisonment 
 Prison response to drug use 
 Effect and potential of the prison 
environment on drug use 
 The most frequently used drug prior 
to imprisonment was cannabis (90%). 
30% and 15% of the sample used 
heroin and methadone respectively 
prior to imprisonment 
 9 individuals were taking methadone 
prior to imprisonment (of whom 3 
were in receipt of a prescription). 
During imprisonment none of the 
participants were prescribed 
methadone yet 2 individuals were 
using in the prison (descriptive data 
only presented)  
Marriot et al. 
(2008) 
UK: 102 male prisoners from 
two Category C prison 
establishments in the same 
geographical region in 
England. Mean age of 28.6. 
88% White, 9% Black, 2% 
Asian, 1% Other. Data 
collected 2002-03.  
Naturalistic study 
following cohorts of 
prisoners through 
two different 
treatment 
modalities 
Establish factors affecting the 
completion of the two different 
treatment modalities;12-step 
programme and cognitive behavioural 
therapy programme (CBT) 
 Post hoc finding of one participant 
taking Methadone medication (at a 
time before Methadone prescribing 
was introduced into prison settings) 
Woodall (2011) UK: prisoners and prison staff 
from three Category C training 
establishments accepting male 
sentenced prisoners in 
England. Gender, age and 
ethnic background of 
participants not stated. Dates 
Focus groups and 
one-to-one 
interviews 
Establish the social and environmental 
factors within the prison setting that 
influence prisoners’ drug taking 
behaviour 
 Drugs were reported by both 
prisoners and staff to be ‘rife’ within 
the prison system 
 The illicit supply of drugs in prison 
were suggested to come through the 
following routes; through visits, 
thrown over the prison wall from 
associates in the community and 
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of data collection not stated. through prisoners diverting their 
medication collected from the prison 
treatment hatches (subutex 
medication specifically mentioned as 
being diverted from the sublingual 
route of administration; one 
participant narrative that there was 
regional variation ie. Subutex abuse 
more likely in northern prisons) 
 Peer-pressure and boredom were 
found to be strong influences on 
drugs misuse in prison  
Wright et al. 
(2015) 
UK: 85 male prisoners 
receiving prescribed opioids 
for heroin dependence from a 
Category B prison 
establishment in the North of 
England. Mean age of 35. 71 
White, 5 Asian-Pakistani, 3 
other Asian background, 2 
mixed – White and Asian, 2 
other Black background, 1 
other mixed background, 1 
other ethnic group. Data 
collected July 2012-October 
2013.  
Cross-sectional 
survey 
To explore the price differentials of 
diverted buprenorphine-naloxone, 
buprenorphine and methadone in the 
prison setting 
 Methadone was reported to be 
significantly harder to sell in the 
prison setting than buprenorphine (X2 
35.1 p<0.001) and buprenorphine-
naloxone (X2 29.1 p<0.001) 
 Prisoners reported the cost of illicit 
buprenorphine to be more expensive 
than illicit buprenorphine-naloxone 
both inside (z = -4.5, p<0.001 and 
outside of prison (z = -3.6, p<0.001) 
 
